Page last updated: 2024-08-21

aminoimidazole carboxamide and Myotonic Dystrophy

aminoimidazole carboxamide has been researched along with Myotonic Dystrophy in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Al-Rewashdy, A; Bélanger, G; Jasmin, BJ; Ravel-Chapuis, A1
Angelini, C; Brockhoff, M; Castets, P; Chojnowska, K; Eickhorst, C; Erne, B; Frank, S; Furling, D; Rion, N; Rüegg, MA; Sinnreich, M; Wiktorowicz, T1

Other Studies

2 other study(ies) available for aminoimidazole carboxamide and Myotonic Dystrophy

ArticleYear
Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles.
    Human molecular genetics, 2018, 10-01, Volume: 27, Issue:19

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Disease Models, Animal; Humans; Mice; Motor Activity; Muscle, Skeletal; Myoblasts; Myotonic Dystrophy; Protein Kinases; Resveratrol; Ribonucleotides; RNA-Binding Proteins; RNA, Messenger; Trinucleotide Repeat Expansion

2018
Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.
    The Journal of clinical investigation, 2017, Feb-01, Volume: 127, Issue:2

    Topics: Adult; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Female; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Mutant Strains; Middle Aged; Multiprotein Complexes; Muscle Fibers, Skeletal; Muscle Relaxation; Myotonic Dystrophy; Myotonin-Protein Kinase; Ribonucleotides; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2017